UCB May Be Stagnating Today, But Promises There Will Be Growth Tomorrow
This article was originally published in The Pink Sheet Daily
Executive Summary
Generics hit UCB's 2009 sales hard, but the mid-cap pharma is looking to new drugs Cimzia and Vimpat for a return to growth.
You may also be interested in...
Zydus Sets Sight On First US Generic Of UCB’s Briviact
Zydus Cadila has scooped another material ANDA approval from the FDA, with the green light for its generic version of UCB’s Briviact to treat partial-onset seizures.
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.